Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALS 205

Next Previous
X
Search
Drug Profile

ALS 205

Alternative Names: ALS-205; PMX-205

Latest Information Update: 15 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Queensland
  • Developer Alsonex Pharmaceuticals; University of Queensland
  • Class Anti-inflammatories; Antidementias; Cinnamates; Cyclic peptides; Indoles
  • Mechanism of Action Complement C5a inhibitors; Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Motor neuron disease; Parkinson's disease
  • Preclinical Alzheimer's disease; Huntington's disease
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Age-related macular degeneration; Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

  • 15 Dec 2023 ALS 205 is still in phase I trials for Motor neuron disease (In volunteers) in Australia (SC, Injection)
  • 15 Dec 2023 ALS 205 is still in phase I trials for Parkinson's-disease(In volunteers) in Australia (SC, Injection)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Motor-neuron-disease(In volunteers) in Australia (SC, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top